Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.55 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.55 |
| ▸ | DHODH | Q02127 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | F2R | P25116 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | TYK2 | P29597 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30839276 | 0.84 | HPGD (0.61) | HPGDSMN1; SMN2ALDH1A1KCNK3KCNK9 | |
| SCHEMBL24103987 | 0.84 | HPGD (0.61) | HPGDSMN1; SMN2ALDH1A1KCNK3KCNK9 | |
| SCHEMBL533801 | 0.84 | SMN1; SMN2 (0.69) | HPGDSMN1; SMN2ALDH1A1KCNK3KCNK9 | |
| SCHEMBL533724 | 0.82 | CYP1A2 (0.70) | HPGDSMN1; SMN2ALDH1A1KCNK3KCNK9 | |
| SCHEMBL27885922 | 0.81 | HPGD (0.61) | HPGDSMN1; SMN2ALDH1A1KCNK3KCNK9 | |
| SCHEMBL16285490 | 0.81 | SMN1; SMN2 (0.62) | HPGDSMN1; SMN2ALDH1A1KCNK3KCNK9 | |
| SCHEMBL31661220 | 0.81 | ALDH1A1 (0.63) | SMN1; SMN2ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL30954405 | 0.80 | ERCC5 (0.58) | HPGDSMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL7472715 | 0.80 | ERCC5 (0.58) | HPGDSMN1; SMN2ALDH1A1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL533692 | 0.80 | HPGD (0.52) | HPGDSMN1; SMN2ALDH1A1KCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2261215-B1 | Process for preparing benzazepine compounds or salts thereof | OTSUKA PHARMA CO LTD (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-8501730-B2 | Process for preparing benzazepine compounds or salts thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-8273735-B2 | Process for preparing benzazepine compounds or salts thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20120226034-A1 | PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-09-06 | — | — | US | disclosed |
| EP-2251319-B1 | Process for preparing derivatives of benzoic acid | OTSUKA PHARMA CO LTD (JP) | 2012-02-08 | — | — | EP | disclosed |
| EP-1919874-B1 | PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF | OTSUKA PHARMA CO LTD (JP) | 2011-01-26 | — | — | EP | disclosed |
| EP-2261215-A1 | Process for preparing benzazepine compounds or salts thereof | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-12-15 | — | — | EP | disclosed |
| EP-2251319-A2 | Process for preparing derivatives of benzoic acid | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-11-17 | — | — | EP | disclosed |
| US-20090306369-A1 | PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-1919874-A2 | PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF | Otsuka Pharmaceutical Company, Limited (JP) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007026971-A2 | PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306369-A1 | PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF | AVPR2, AVPR1B, AVPR1A | HPGD 1043/4885SMN1; SMN2 2293/4885ALDH1A1 876/4885 |
| US-20120226034-A1 | PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF | AVPR2, AVPR1B, AVPR1A | HPGD 1043/4885SMN1; SMN2 2293/4885ALDH1A1 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.